The Editorial Office is pleased to answer any questions you may have about preparing your manuscript in accordance with our guidelines.
Email: BBRCR@pub.hep.cn
Bone and Bone Related Cancer Research (BBRCR) is dedicated to advancing the understanding of bone biology and bone-related cancers. The journal publishes high-quality, peer-reviewed research articles, reviews, and clinical studies that explore all aspects of bone research and the pathophysiology, diagnosis, and treatment of bone-associated malignancies.
The primary focus of the journal is to bridge the gap between basic bone biology and clinical applications in the context of cancer, providing insights into the molecular mechanisms underlying bone metabolism, tumor-bone interactions, and the development of bone-related cancers such as osteosarcoma, bone metastasis, and multiple myeloma. Topics of interest include, but are not limited to:
● Molecular and cellular mechanisms of bone metabolism
● Genetic and epigenetic factors in bone development and malignancy
● Tumor-bone microenvironment interactions
● Innovative therapeutic strategies for bone cancer
● Advances in diagnostic technologies for bone-related cancers
● Mechanisms of bone metastasis in solid tumors
● Role of stem cells and bone regeneration in cancer treatment
● Clinical trials and treatment outcomes for bone cancer therapies
The journal aims to foster interdisciplinary collaborations and provide a comprehensive platform for researchers, clinicians, and healthcare professionals interested in bone health and bone cancer research.
Please click the Register button at https://www.editorialmanager.com/bbrcr/default.aspx. Upon successful registration, you will be sent an email providing your username and password. Save this information for future reference.
Note: If you have received an email from us with an assigned username and password, or if you are a repeat user, do not register again. Once you have an assigned username and password, you do not have to re-register.
Please click the Login button from the menu at the top of the page and login to the system as an author. Submit your manuscript according to the author instructions. You will be able to track the process of your manuscript through the system.
Bone and Bone Related Cancer Research expects that each person listed as an author has participated sufficiently in the intellectual content, the analysis of data, and/or the writing of the manuscript to take public responsibility for it. Each author must have reviewed the manuscript, believes it represents valid work, and approves it for submission.
Moreover, should the Editorial team request the data upon which the manuscript is based, the authors shall produce it. Each author's specific contributions to the work should be indicated; this information will be published as a footnote to the paper. For example, the areas of participation might include:
● Participated in research design
● Participated in the writing or critical revision of the paper
● Participated in the performance of the research
● Contributed new reagents or analytic tools
● Participated in data analysis
An author may list more than one contribution, and more than one author may have contributed to the same aspect of the work. Any change in authorship/contributions after submission must be approved in writing by all authors and submitted to the Editorial Office for final consideration.
Authors are fully responsible for the content of their manuscript, even those parts produced by GenAI. Authors who have used GenAI in their research and the writing of manuscripts should provide an open, transparent, and detailed description of the use of GenAI (including the name and version of the GenAI tool, when it was used, how it was used, and the process of using it, and, if necessary, annotations for AI-assisted contents dealing with facts and opinions), and review of GenAI, following the body of the text, before the references, or in the method section (e.g., the authors have reviewed and edited the GenAI-produced content, and take full responsibility for the authenticity and accuracy of the content of this paper). It is recommended that authors submit and archive the GenAI-assisted sections (text, figures, programs, etc.) as supplementary material so that reviewers and editors can judge the accuracy, integrity，and originality of the paper.
Since GenAI cannot meet the requirements for authorship as they cannot take responsibility for the submitted work, GenAI -related products and developing teams cannot be listed as the author of a paper.
GenAI cannot be used to write an entire paper or a significant portion of a paper (e.g., method, result and analysis, etc.). All content that falls under the category of scientific contribution or intellectual labor should be finished by the author. If the main content of the paper is completed using GenAI, the editorial office will handle it as academic misconduct.
As defined by the World Association of Medical Editors (http://www.wame.org/resources/publication-ethics-policies-for-medical-journals), plagiarism is the use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission, and presenting them as new and original rather than derived from an existing source. The intent and effect of plagiarism is to mislead the reader as to the contributions of the plagiarizer. This applies whether the ideas or words are taken from abstracts, research grant applications, Institutional Review Board applications, or unpublished or published manuscripts in any publication format (print or electronic).
Bone and Bone Related Cancer Research is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a plagiarism screening service that verifies the originality of content submitted before publication. iThenticate checks submissions against millions of published research papers, and billions of web content. Authors, researchers and freelancers can also use iThenticate to screen their work before submission by visiting http://www.ithenticate.com.
All allegations of plagiarism are investigated in accordance with the Committee on Publication Ethics (COPE) guidelines detailed at https://publicationethics.org/files/u7140/plagiarism%20A.pdf. When plagiarism is detected at any time before or after publication, the journal editorial office will take appropriate action as directed by the standards set forth by COPE. If plagiarism is found, the author, the author's institution and funding agencies, and the original publication will be notified. A statement noting the plagiarism, providing a reference to the plagiarized material, and linking to the original paper may follow. Depending on the extent of the plagiarism, the paper may also be formally retracted. For additional information, please visit http://www.publicationethics.org.
Appropriate use of the English language is a requirement for publication in the Bone and Bone Related Cancer Research. Authors having difficulty in writing in English who submit manuscripts to international journals often receive negative comments from referees or editors about the English-language usage in their manuscripts, and these challenges can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors consider using Wolters Kluwer Author Services**.
Wolters Kluwer, in partnership with Editage, offers a unique range of editorial services to help you prepare a submission-ready manuscript:
● Premium Editing: Intensive language and structural editing of academic papers to increase chances of journal acceptance.
● Advanced Editing: A complete language, grammar, and terminology check to give you a publication-ready manuscript.
● Translation with Editing: Write your paper in your native language and Wolters Kluwer Author Services will translate it into English, as well as edit it to ensure that it meets international publication standards.
● Plagiarism Check: Helps ensure that your manuscript contains no instances of unintentional plagiarism.
● Artwork Preparation: Save precious time and effort by ensuring that your artwork is viewed favorably by the journal without you having to incur the additional cost of purchasing special graphics software.
For more information regarding Wolters Kluwer Author Services, please visit http://wkauthorservices.editage.com.
**Note that the use of such a service is at the author's own expense and risk, and does not guarantee that the article will be accepted.
Bone and Bone Related Cancer Research operates a single-blind external peer review process, wherein the reviewers are aware of author's identity, however the authors don't. Brief introduction on editorial review process of the journal:
On submission, editors review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the readers of the journal are also liable to be rejected at this stage.
Manuscripts that are found suitable for potential publication of the journal are sent to a minimum of two independent expert reviewers to assess the scientific quality of the manuscript. Authors submitting manuscripts to Bone and Bone Related Cancer Research may propose suitable reviewers or oppose reviewers who may have competing interests. The proposed reviewers should not be affiliated with the same institutes as the contributor(s). However, the selection of these reviewers is at the sole discretion of the editor, who selects reviewers to reflect relevant expertise, diversity, and geographical backgrounds.
Peer reviewers have access to the submitted manuscript and any appendices included by the authors. If the paper is a randomized controlled trial, peer reviewers will also have access to the trial protocol. Peer review assists editors in their decision on whether to publish an article and helps authors revise and improve their manuscripts. Peer reviewers make suggestions for improvements, critique the analysis, point out relevant published work which is not yet cited, and provide recommendations to the authors and the editors. At Bone and Bone Related Cancer Research, reviewers are aware of authors' identities, meantime, reviewers' comments are sent to the authors anonymously. Details of peer review including dates and peer review comments are not shared publicly. Reviewed articles are treated confidentially prior to their publication.
Based on the comments from the reviewers, the handling editor takes an acceptance decision on the manuscript and convey the comments and suggestions (acceptance/ rejection/ amendments in manuscript) to the corresponding author, who is requested to provide a point-by-point response to reviewers' comments and submit a revised version of the manuscript. This process is repeated until reviewers and editors are satisfied with the manuscript. Manuscripts are accepted on the basis of quality, originality, significance, novelty, and importance for the field.
Manuscripts received from Editorial Board Members will be screened by the Editor-in-Chief and sent to external peer reviewers. The Editorial Board Members, who submit manuscripts to the journal as authors or co-authors, will be excluded from publication decisions.
Manuscripts received from Editor-in-Chief will be handled by the other co-Editor-in-Chief or one of the Associate Editor of the journal and will be sent to external peer reviewers. The contributing Editor-in-Chief will be excluded from decision-making of his/her manuscript.
Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or whoever relate to products or services in which the editor has an interest. Any such submission is subject to the journal's standard procedures, with peer review handled independently of the relevant editor and their research groups.
All guest editors should have expertise in the chosen topic as evidenced in their research activities and publication record. A guest editor will typically be responsible for soliciting papers under the overseer of EiC and won't be involved in editorial and peer review process.
Peer Reviewing Procedure of all articles appearing in the special issues should conform to the standard editorial and publication policies as outlined for the journal. Although appearing as part of a special issue, all articles should conform to the same quality standard as any journal paper. This implies that each manuscript will be original, not be published elsewhere in a journal and will be peer reviewed by at least two specialists in the field. The Editor-in-Chief follows best practice guidance provided by the Publisher on avoiding the selection of fraudulent peer reviewers.
The authors have the right to appeal if they have a genuine cause to believe that the editorial board has wrongly rejected the paper. If the authors wish to appeal against the editorial decision, they should email the editorial office (email: BBRCR@pub.hep.cn) explaining in detail the reason for the appeal. The appeals will be acknowledged by the editorial office and will be investigated in an unbiased manner. The processing of appeals will be done within 6–8 weeks. While under appeal, the said manuscript should not be submitted to other journals. The final decision rests with the Editor-in-Chief of the journal. Second appeals are not considered.
TYPES OF MANUSCRIPTS PUBLISHED
Original Research: It is full-length reports of completed basic, translational, or clinical research. Articles should report important, novel and fully completed studies with strong conclusions. There is also no clear limit on the length of the submitted paper, but authors are encouraged to be concise, preferably within 2500-6000 words. Articles have a structured abstract of maximum 400 words, including Background, Objectives, Methods, Results and Conclusions. The number of references is not limited.
Review: Bone and Bone Related Cancer Research welcome rigorous, balanced reviews on topics of interest to the field. If you have a concern about whether your topic fits within the scope of the journal, please contact the journal's editor. All review articles undergo the same peer-review and editorial process as original research reports.
Consensus and Guideline: Official recommendations from professional organizations on issues related to clinical practice and health care delivery. CMJ is flexible with length, reference, and other format requirements given the variability in the format of guidelines developed by different organizations. A concise table or concise graphic summarizing the recommendations and other key points is desirable. Guidelines that meet standards (http://www.equator-network.org/) will fare more favorably than those that do not.
Case Report: New, interesting and rare cases can be reported. They should be unique, describing a great diagnostic or therapeutic challenge and providing a learning point for the readers. Cases with clinical significance or implications will be given priority. These communications could be of up to 1,000 words (excluding Abstract and references) and should have the following headings: Abstract (unstructured), Key-words, Introduction, Case report, Discussion, Reference, Tables and Legends in that order. All the components that are required in Abstract (unstructured) based on the reporting guidelines (CARE).
Letter: Information of a high interest to the community and information on other pertinent subjects should be submitted as a Letter to the Editor. Letters are expected to provide substantive comments on papers published in the journal within the previous 6 months. Letters may be sent for peer review. A second type of Letter includes comments on articles already published in Bone and Bone Related Cancer Research. The authors of the original publication will be contacted for a response, which if accepted, will publish in the same issue as the Letter to the Editor.
Editorials: It is invited articles to explain the importance of specific articles or to provide opinions on general concepts in practice, research, or policy.
Registration of Clinical Trials is an essential requirement for publication of clinical trials in Bone and Bone Related Cancer Research. On the title page of your manuscript, provide the name of the trial registry and the registration number/identifier of the trial.
Acceptable web-based clinical trial registries include the following:
● EudraCT at https://eudract.ema.europa.eu for EU trials
● ClinicalTrials.gov at www.clinicaltrials.gov for US trials
● Current Controlled Trials found at www.controlled-trials.com
● WHO International Trial Registry Network found at http://www.who.int/ictrp/network/primary/en/index.html
● Australian & New Zealand Clinical Trials Registry, found at http://www.anzctr.org.au/
● Chinese Clinical Trail Registry (https://www.chictr.org.cn)
● And any publicly available primary registry of clinical trials
Reports of randomized clinical trials should follow the recommendations given in the Consolidated Standards of Reported Trials (CONSORT) statement http://www.consort-statement.org. In brief, this statement comprises a checklist and flow diagram to help improve the quality of reports of randomized controlled trials and offers a standard way for researchers to report trials.
The following resources may be helpful to authors:
● PRISMA –Preferred Reporting Items for Systematic Reviews and Meta-Analyses http://www.prisma-statement.org
● STROBE - Strengthening the Reporting of Observational studies in Epidemiology http://www.strobe-statement.org
● CARE - CAse REports https://www.care-statement.org/
Qualitative research provides in-depth insights about people's values, attitudes, beliefs, and experiences. Qualitative methodology informs approaches to data collection and analysis, and includes grounded theory, ethnography, and phenomenology. Open-ended interviews and focus groups are commonly used to collect data. Authors are advised to follow the COREQ guidelines for reporting primary qualitative research. Please visit: http://intqhc.oxfordjournals.org/content/19/6/349.full.pdf
Systematic review and/or synthesis of primary qualitative studies can provide a broader understanding of people's perspectives. Methodologies for synthesis of qualitative research include thematic synthesis, meta-ethnography, and critical interpretive synthesis. Authors can refer to the ENTREQ statement at
http://www.biomedcentral.com/content/pdf/1471-2288-12-181.pdf
A financial disclosure section is part of the submission process and must be completed by each author at first revision. This information is for review by the Editors but will be published if relevant to the content of the accepted manuscript. The primary purpose of the disclosure section is to determine whether authors have received any commercial financial support that could create a conflict of interest. In addition to monetary interests, a potential for conflict of interest can exist whether or not an individual believes that a relationship (such as dual commitments, competing interests, or competing loyalties) affects his or her scientific judgment. Please review ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals at the following link: http://www.icmje.org/conflicts-of-interest.
Manuscripts must be written in clear, grammatical English (see English Language Assistance above). Manuscripts not conforming to Journal format will be returned to authors for modification. Please double space the entire main body document and number each page. Do not add line numbers as the system will generate those when the PDF is built.
Original Research Articles should include the sections listed below.
1. Title Page
2. Abstract
3. Introduction
4. Methods
5. Results
6. Discussion (with a labeled Conclusion)
7. Conflict of Interest
8. Funding
9. Acknowledgments
10. References
The title page must include:
a. Title of the article. Titles should clearly and concisely describe the contents of the paper and include the animals, participants, or cells studied.
b. The names of all authors (first name, middle initial, last name)
c. Author Affiliations (departmental and institutional) at the time the research was done.
d. Disclaimers, if any.
e. Sources of support for the work; include sponsor names along with explanations of the role of those sources if any in study design; collection, analysis, and interpretation of data; writing of the report; any restrictions regarding the submission of the report for publication; or a statement declaring that the supporting source had no such involvement or restrictions regarding publication.
f. Conflict of Interest and Funding Disclosure – List any existing financial arrangements between an author and a company whose product figures prominently in the submitted manuscript or between the author and any company or organization sponsoring the research reported in the submitted manuscript. If an author has no conflicts of interest, list the author's name, followed by “no conflicts of interest." Additional guidance is provided under Journal Policies, Conflicts of Interest.
g. Corresponding Author's name, mailing address, telephone number, and e-mail address
A properly constructed and informative abstract is helpful for the initial editorial review of the submitted manuscript. Original research articles must include a structured abstract that contains no more than 400 words, is written in complete sentences, and includes the following headings:
Background: Provide 1 or 2 sentences that explain the context of the study.
Objective: State the precise objective, the specific hypothesis to be tested, or both.
Methods: Describe the study design, including the use of cells, animal models, or human subjects. Identify the control group. Identify specific methods, procedures, and if appropriate, statistical analysis used. Describe interventions, if used.
Results: Report the most important findings, including results of statistical analyses.
Conclusions: Summarize in 1 or 2 sentences the primary outcomes of the study, including their potential clinical importance, if relevant (avoid generalizations). Include the participants, animals, or cells studied.
(If applicable) Clinical Trial Registry number and website where it was obtained (please provide a direct link to the trial page, preferably the English-language version).
(If applicable) Registry and registry number for systematic reviews or meta-analyses. An appropriate registry for systematic reviews and meta-analyses is PROSPERO. Please note that PROSPERO does not allow for post-completion registration of studies.
(Advances only) add a 1-2 sentence Statement of Significance indicating explicitly what is truly new in the present work compared to work already published in the field
Review articles, special articles, and reports should include an unstructured abstract (no more than 400 words) that states the purpose of the article and emphasizes the major concepts and conclusions.
Any abbreviations used in the abstract should be defined in the abstract at first mention.
Below the abstract, provide 5–10 keywords or short phrases, including the subject group, that will help to increase the discoverability of your manuscript; do not use adjectives. Terms that are fundamental to your manuscript but are not included in your manuscript title or abstract are especially important to include to increase discoverability by indexing services such as PubMed.
Please note that during manuscript submission, you will be asked to supply keywords to assist the editors in identifying suitable reviewers for your manuscript. Keywords for reviewer searches should include the terms most fundamental to your manuscript and may differ from your list of keywords for publication.
Describe clearly the background to the research conducted and the specific objectives. This should not be a comprehensive review of the literature, however. State the specific objective or hypothesis of the study. Do not include methods, data, results, or conclusions from the work being reported.
Documentation of methods and materials used should be sufficient to permit replication of the research. Describe clearly the experimental design including the control and experimental groups and provide eligibility and exclusion criteria and details of randomization. Define all group designations parenthetically at first mention [for example, “control (CON) and high-fat (HF) groups"] and include definitions for these abbreviations in the abbreviation footnote on the title page. Describe the methods for, and success of, any masking (blinding) of observations. Report any complications of experimental treatments.
State the product name and manufacturer of specialized materials, diets, chemicals, and instruments and other equipment, where appropriate. Specify kits, analyzers, and commercial laboratories used. Identify precisely all drugs and chemicals used, including generic names, dosages, and routes of administration. If trade names for drugs and chemicals are included, give the manufacturer's name and location. Do not use trademark names, such as Teflon, as generic terms. Give references for established methods, including statistical methods; provide references and brief descriptions of methods that have been published but are not well known; and describe new or substantially modified methods, giving reasons for using them and evaluating their limitations.
Animal Diets. Composition of control and experimental diets must be presented. When a diet composition is published for the first time in Bone and Bone Related Cancer Research, provide complete information on all components in a table. If previously described in Bone and Bone Related Cancer Research, a reference may be cited. State specifically any modifications made to the published diet compositions. The proximate composition of closed formula diets should be given as amounts of energy, protein, fat, carbohydrate, and fiber. For diets varying in energy density, include percent energy contributions from protein, fat, and carbohydrate. Vitamin and mineral mixture compositions should be included using units and nomenclature as described below. For discussion of the formulation of purified animal diets, refer to the following publications.
Pellizzon MA and Ricci MR. Choice of Laboratory Rodent Diet May Confound Data Interpretation and Reproducibility. Curr Dev Nutr 2020;4:nzaa031.
Baker DH. Problems and pitfalls in animal experiments designed to establish dietary requirements for essential nutrients. J Nutr 1986;116:2339–49.
American Institute of Nutrition. Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. J Nutr 1977;107:1340–48.
American Institute of Nutrition. Second report of the ad hoc committee on standards for nutritional studies. J Nutr 1980;110:1726.
American Institute of Nutrition. Guidelines for describing diets for experimental animals. J Nutr 1987;117:16–7.
American Institute of Nutrition. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939–51.
The experimental diets should differ from the control diets only in the nutrient(s) being investigated. Nonpurified diets generally should not be used as control diets in rodent species; rodents fed these diets generally should be included for reference only and their data should not be included in the statistical analysis.
Present your results in a logical sequence in the text, tables, and figures. Do not present specifics of data more than once and do not duplicate data from tables or figures in the text. Do not present data from individual subjects except for very compelling reasons. Report losses to observation (such as dropouts from a clinical trial). Use boldface for the first mention of each table or figure.
Emphasize concisely the important aspects of the study and the conclusions that follow from them. Do not repeat in detail data or other material given in the Introduction or Results. Include the implications of the findings and their limitations and relate the observations to other relevant studies. Link conclusions with the goals of the study and avoid unqualified statements and conclusions that are not completely supported by the data. Avoid claiming priority and alluding to work that has not been completed. State new hypotheses and recommendations when warranted by the results and label them clearly as such.
All authors must disclose any conflict of interest.
Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Details must be included at the end of your manuscript and in a file that must be uploaded on submission. We recommend you use the ICMJE standard form to help you prepare this declaration. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See alsohttp://www.icmje.org/conflicts-of-interest.
List funding sources in this standard way to facilitate compliance to funder's requirements for example:
"This work was supported by the Institutes A [#123]; Company B, Seattle, WA [#456]; and the Association C [#789]"
When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding. If no funding has been provided for the research, please include the following sentence:
"This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors."
Acknowledge only persons who have made substantive contributions to the study. Technical assistance and advice may be acknowledged. Include only named individuals in this section.
The journal uses American Medical Association (AMA) style. References should begin on a separate page and numbered in the order in which they are cited in the text, where they are designated by superscript numbers placed outside periods and commas, and inside colons and semicolons. Only published works and manuscripts that have been accepted for publication should be listed in the References. Manuscripts in preparation, unpublished observations, and personal communications should be referred to in parentheses in the text. Completed manuscripts submitted for publication may be cited as footnotes to the text (see above, Footnotes). If these are subsequently accepted, the author may transfer them to the reference section in galley proof.
References Format. No more than six authors should be listed. If there are seven or more, only the first three followed by ''et al.'' should be included. Titles of journal articles must be included, and abbreviation of journal names should conform to Index Medicus style.
For information on AMA style, please visit http://www.amamanualofstyle.com.
Two authors:
Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med. 2011; 15(7): 1458-73.
More than seven authors:
Ali JM, Bolton EM, Bradley JA, et al. Allorecognition pathways in transplant rejection and tolerance. Transplantation 2013; 96(8): 681-8.
Organization as author:
CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57(RR-5): 1-30.
Tables: Photographs of tables are not acceptable. Type each table, double-spaced throughout (including column headings, footnotes, and data), on a separate page. Tables may be included as part of the Main Body file and placed after the References section. Number the tables in sequence in Arabic numerals and supply a concise, informative title for each one. Each column in the tables should carry a concise heading describing the data in the column. Use lowercase superscript letters to designate footnotes, and type the footnotes below the tables to which they refer. Tables are cited in the text in numerical order. Each table should be able to be understood without consulting the text.
Like text, tables should be prepared using a standard word-processing program and may be included within the main body text document or uploaded separately. Do not upload table files more than once (that is, in the main document and in separate files).
Acceptable document file types for tables include .DOC and .DOCX; do not submit PDF, XLS or XLSX type files.
Figures and Legends: Figures should be uploaded in the highest resolution available. Legends should be supplied for all figures. They are numbered to correspond with the figures and typed double-spaced on a separate page. Figure legends for any supplemental figures being submitted are to be provided separately; see section, Supplemental Digital Content (SDC).
Acceptable figure file formats
● Do not embed figures into the main body file
● All final digital figures for accepted manuscripts must be submitted in EPS, TIFF, JPG. PowerPoint PPT format is permitted when the image resolution is very high.
● Each figure must be uploaded as a separate file.
● Histology figures must be in color.
● Monochrome images (such as line graphs) should be prepared at a resolution of 1200 DPI.
● Halftones images (black/white or color) should be prepared at a resolution of 300 DPI.
● Combination halftones (images containing both pictures and text labeling) should be prepared at 600 DPI.
● Color images must be saved as ''CMYK''. Images saved as ''RGB'' are not acceptable for printing.
● Your manuscript may be returned to you for correction if the images are of insufficient quality.
● Artwork submitted to the Journal will be checked for quality. Authors submitting a revised paper will have the opportunity to check the quality of their images and make the necessary changes. This step is required for all revisions.
Supplemental Digital Content (SDC): Authors may submit Supplemental Digital Content to supplement the information provided in the manuscript. It is preferable to include all significant figures and tables in the manuscript, since there is not a limit on the number of items in this online journal. Nonetheless, SDC may include the following types of content: text, tables, figures, references peripheral to information provided as SDC, audio, and video. SDC should be consecutively cited in the Main Body text of the submitted manuscript. SDC files will be available via URL(s) placed at the citation points within the article and are not copyedited by the publisher. Note that Journal policies for manuscript submission relating to peer review, patient anonymity, ethics, financial disclosure, copyright, and permissions also apply to SDC. Authors should mask patients' eyes and remove patients' names from supplemental digital content unless they obtain written consent from the patients and submit them as supplemental files at the time of the manuscript submission.
Format, File Type and Size Requirements: SDC must be provided in one Word or PowerPoint file. Each SDC in the file should have a visual header in the following name format (e.g., ''SDC, Figure 1''; ''SDC, Materials and Methods'') and a corresponding citation must appear in the Main Body text. Note that SDC is numbered separately from non-SDC material. If providing SDC figure(s), a figure legend should be included on the figure itself. When uploading SDC select ''Supplemental Digital Content'' as the file designation. For audio and video files, also include the author's name, videographer, participants, length (minutes), and size (MB). Video files should be formatted with a 320x240 pixel minimum screen size. For each submission, the SDC file cannot exceed a total size of 10 MB.
Once the manuscript has been created, visit the submission site at https://www.editorialmanager.com/bbrcr/default.aspx. to upload the manuscript. Once the manuscript has been vetted for compliance to the Journal's requirements, a manuscript number will be assigned to the submission. Failure to adhere to these guidelines will result in your manuscript being returned to you for correction. Faxed, scanned, or emailed copies of manuscripts will not be accepted.
Mandatory Author Forms: Upon first submission, the corresponding author will be required to complete a License to Publish Form (LTP) online during the submission process. Manuscripts will not pass to production without completion of this step. LTP terms and conditions are available from the submission site homepage https://www.editorialmanager.com/bbrcr/default.aspx.
All revised submissions require a point-by-point response to the reviewers' comments. Please upload this document as file type Response to Reviewers.
Changes made in the revised manuscript should be indicated using highlighted, bold, or underlined text. Upload both a Marked and a Clean version of the revised manuscript. File types are provided for both versions.
A requirement of all revisions is the artwork quality check as described above (see Figures and Legends).
Revised manuscripts should be submitted within the deadline specified in the decision letter. Please contact us for an extension of the due date if it is not possible to submit the revision within that period, or should you desire to withdraw the manuscript from further consideration.
Revisions should adhere to original specifications for the submission type. Sometimes changes made in response to the decision/critiques may bring the revised manuscript out of compliance (e.g., over the word count and/or table/figure limit) with original specifications. This may be allowed by the Editor but must be noted in the point-by-point response.
Authors may want or be invited to submit videos to the Journal's website. The videos will serve to emphasize key aspects of the research findings reported in their soon to be published manuscript. Please visit Stand Alone Video Format Requirements https://bit.ly/VMxbrb to download full specifications and instructions for preparing these invited videos.
The publisher's Journal Production Editor will contact you when page proofs are ready for your review. The figures included on author's proofs are high resolution. Please inform the Journal Production Editor immediately if you have any questions concerning the quality of the figures on the proofs. For information regarding proofs, or the status of publication of your accepted manuscript, please contact the editorial office here: BBRCR@pub.hep.cn
Changes in Corresponding Author's Contact Information
Please give all new information, including email address, to the editorial office and to the publisher. Authors may send this information to the editorial office here: BBRCR@pub.hep.cn. If the Journal is unsuccessful in contacting the corresponding author, the author will not receive proofs for approval, and the manuscript may not be published.
It is expected that the final manuscript sent to the Editor is indeed the final version, so few changes should be required at proof stage.
Authors retain their copyright for all articles. Authors grant WK a license to publish the article and identify itself as the original publisher. The article publishing charge (APC) is currently waived for this journal. Editorial Office of Bone and Bone Related Cancer Research will pay to make the articles open access.
Open access articles will be freely available to read, download and share from the time of publication. Bone and Bone Related Cancer Research provides authors the Creative Commons 4.0 licenses defined below.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered.
The Journal is compliant with the NIH Public Access Policy. Please refer to the Publisher's page for more details.
The Editorial Office is pleased to answer any questions you may have about preparing your manuscript in accordance with our guidelines.
Email: BBRCR@pub.hep.cn
Submit a manuscript: https://www.editorialmanager.com/bbrcr/default.aspx